Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Legha

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
Melanoma Research|June 4, 1998
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapyC M Anderson, A C Buzaid, J Sussman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trialOmar Eton, Sewa S Legha, Agop Y Bedikian, et al.
Melanoma Research|January 26, 1999
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastasesA C Buzaid, M Colome, A Bedikian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic factors for survival of patients treated systemically for disseminated melanomaO Eton, S S Legha, T E Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging systemA C Buzaid, M I Ross, C M Balch, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanomaJ L Murray, E S Kleinerman, S F Jia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanomaO Eton, D D Kharkevitch, M A Gianan, et al.
Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Melanoma Research|June 4, 1998
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapyC M Anderson, A C Buzaid, J Sussman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trialOmar Eton, Sewa S Legha, Agop Y Bedikian, et al.
Melanoma Research|January 26, 1999
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastasesA C Buzaid, M Colome, A Bedikian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic factors for survival of patients treated systemically for disseminated melanomaO Eton, S S Legha, T E Moon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging systemA C Buzaid, M I Ross, C M Balch, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanomaJ L Murray, E S Kleinerman, S F Jia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanomaO Eton, D D Kharkevitch, M A Gianan, et al.
Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
Pageof 18